Investment trusts with a US focus or those with holdings in resource companies and US banks performed well in November following Donald Trump's win to become the 45th President of the United States.
As expected, immediately after President-Elect Trump's (pictured) victory, biotech and healthcare investment trusts saw a significant turnaround in performance after months of volatility. As the threat of pricing controls from a potential Clinton win receded, funds such as Biotech Growth trust and International Biotechnology trust were big winners in NAV terms, up by 5.5% and 6% respectively, accord to figures from QuotedData. But some funds saw higher returns, such as Jupiter US Smaller Companies and JPMorgan US Smaller Companies, which were up 6.7% and 6.5% in NAV terms, respectivel...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
